Database

Startups

Main Industry
Health Care
Main Product/Service
1. C62 / L154
2. neo Series
3. neo Vet Series
Founded Year
2019
Unified Business No.
82815411
Status
Active
Number of Employees
0
Total Paid-in Capital
127,280,995 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
Aco Healthcare Co., Ltd., operating under the brand name Aco Smartcare, was founded in 2019. In that same year, we became a subsidiary of Compal Group. Our team specialize in designing and manufacturing in various sectors, including hardware, software, and transducer modules. ​


Our strength lies in developing advanced technology solutions that fulfill clinical needs, optimize workflow, and meet customization requirements. We consistently deliver high-quality products and are committed to providing excellent post-sales support to our valued customers.



More ↓

Similar Companies

Insight Medical Solutions Technologies Inc.

1. Aries E500i
2. InsightEyes EGD
3. InsightEyes EGD Dongle
4. InsightEyes MFN
5. 21.5" LCD Monitor

世創生物科技股份有限公司

Breath-Care
Enosim developed the ASTRON, a real-time monitoring and identification breath analysis system for Ventilator-Associated Pneumonia (VAP).

Ventilator-associated pneumonia refers to a bacterial lung infection in intensive care units(ICU), and the patients have been treated with a respirator for more than 48 hours. VAP is the most common nosocomial infection in ICU, and the rate of infection is about 7 to 14%. The mortality rate can reach from 35 to 90%. According to the US study, the additional medical expenses is about US$ 40,000 (about NT$1,280,000). The current species diagnosis relies on the experience of clinical physicians . And the sputum culture to identify bacterium can only get the sucess rate about 60% after 3 to 5 days.

In ICU, there is a umment medical need for the rapid VAP identification. In Taiwan, the number of people in the ICU has increased by 2.4 times in past ten years. However, the patient who leaving rate from respiratory is only 70%, the rate of demanding is reached 142%. The cost as reached NT$4.2 billion.